CAS 188627-80-7

Eptifibatida

Descrição:

Eptifibatida é um heptapeptídeo cíclico sintético que funciona como um potente agente antiplaquetário, utilizado principalmente no manejo de síndromes coronários agudos e durante intervenções coronárias percutâneas. Atua como um inibidor reversível do receptor de glicoproteína IIb/IIIa nas plaquetas, prevenindo assim a agregação plaquetária e a formação de trombos. Eptifibatida é derivado do veneno da cascavel pigmeia do sudeste e é caracterizado por sua afinidade de ligação específica ao receptor, que é crucial para a ativação plaquetária. A substância é tipicamente administrada por via intravenosa e tem uma meia-vida relativamente curta, necessitando de infusão contínua em ambientes clínicos. Eptifibatida geralmente é bem tolerado, embora possa estar associado a riscos de sangramento, particularmente em pacientes com histórico de distúrbios hemorrágicos ou aqueles que estão se submetendo a procedimentos cirúrgicos. Sua farmacocinética e farmacodinâmica fazem dele uma ferramenta valiosa no cuidado cardiovascular agudo, contribuindo para a melhoria dos resultados em pacientes de alto risco.

Fórmula: C₃₅H₄₉N₁₁O₉S₂

InChI: InChI=1/C35H49N11O9S2/c36-31(52)26-17-57-56-12-10-27(47)43-22(7-3-4-11-39-35(37)38)32(53)41-16-28(48)44-25(14-29(49)50)34(55)45-24(13-18-15-40-20-6-2-1-5-19(18)20)30(51)21-8-9-23(42-21)33(54)46-26/h1-2,5-6,15,21-26,40,42H,3-4,7-14,16-17H2,(H2,36,52)(H,41,53)(H,43,47)(H,44,48)(H,45,55)(H,46,54)(H,49,50)(H4,37,38,39)/t21?,22-,23-,24-,25-,26-/m0/s1

SMILES: c1ccc2c(c1)c(C[C@H]1C(=O)C3CC[C@@H](C(=N[C@@H](CSSCCC(=N[C@@H](CCCCNC(=N)N)C(=NCC(=N[C@@H](CC(=O)O)C(=N1)O)O)O)O)C(=N)O)O)N3)c[nH]2

Sinónimos:

• [3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
• [(1S,4R,12S,18S,21S)-12-(4-carbamimidamidobutyl)-4-carbamoyl-21-(1H-indol-3-ylmethyl)-2,10,13,16,19,22-hexaoxo-6,7-dithia-3,11,14,17,20,26-hexaazabicyclo[21.2.1]hexacos-18-yl]acetic acid
• Map-Lys-Gly-Asp-Trp-Pro-Cys-Nh2
• Integrelin
• N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide
• [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
• Eptifibatide Acetate

Eptifibatide

CAS: 188627-80-7

Eptifibatide, a RGD mimetic, is a glycoprotein (GP) IIb/IIIa receptor antagonist. Clinically, the peptide is used as an antiplatelet drug in combination with heparin and aspirin in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures. CAS Number (eptifibatide acetate): 148031-34-9.

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: ≥99%

Cor e Forma: White Lyophilisate

Peso molecular: 831.97

Ref: 01-4063191

Eptifibatide

CAS: 188627-80-7

Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoi

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Cor e Forma: White Powder

Peso molecular: 831.31561

Ref: 45-1238501

L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1→6)-disulfide

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: 96%

Cor e Forma: Solid

Peso molecular: 831.9619

Ref: IN-DA001FDT

Eptifibatide

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Peso molecular: 831.96

Ref: 7W-GP0493

Eptifibatide Acetate

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: 95%~99%

Cor e Forma: White to Off-white Powder

Peso molecular: 831.962

Ref: BP-BPPG027

Eptifibatide

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Peso molecular: 831.97

Ref: 4Z-PE-126001

Human Eptifibatide

CAS: 188627-80-7

Human Eptifibatide

Cor e Forma: White Lyophilised Powder

Peso molecular: 831.96g/mol

Ref: 54-BITP1545

Eptifibatide

Produto Controlado

CAS: 188627-80-7

Applications An arginine-glycine-aspartate-mimetic, reversibly binds to platelets to reduce the risk of cardiac ischemic events.
References Pathak, A., et al.: Cardiovas. Diabetol., 7 (2008), Hantgan, R., et al.: Biochem., 48, 8355 (2009), Giugliano, R., et al.: New Eng. J. Med., 360, 2176 (2009),

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Cor e Forma: Off White Solid

Peso molecular: 831.96

Ref: TR-E592000

Eptifibatide acetate

Produto Controlado

CAS: 188627-80-7

Inhibits platelet glycoprotein IIb/IIIa receptors

Fórmula: C₃₅H₄₉N₁₁O₉S₂·xC₂H₄O₂

Pureza: Min. 95%

Cor e Forma: Powder

Peso molecular: 831.96 g/mol

Ref: 3D-FE40869

Eptifibatide

CAS: 188627-80-7

Eptifibatide is a drug that is used in the treatment of congestive heart failure, acute coronary syndrome and peripheral artery disease. It is a glycoprotein IIb/IIIa inhibitor that binds to integrin receptors on platelets and prevents them from binding to fibrinogen. This prevents blood clotting and reduces the risk of stroke or heart attack. Eptifibatide has been shown to be effective for the treatment of bowel disease, infectious diseases, and experimental models of myocardial infarcts. The drug has significant cytotoxicity, which may be due to its ability to inhibit cell proliferation by blocking protein synthesis at the ribosome level.
Eptifibatide has been shown to have a disulfide bond between two cysteine residues located in its amino-terminal region. This bond stabilizes the molecule in solution and ensures that it remains active until it reaches its target site.

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: Min. 95%

Peso molecular: 831.98 g/mol

Ref: 3D-EPT-3786-PI